Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – EurekAlert
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
IMAGE: Tina Cascone, M.D., Ph.D.
view more
Credit: MD Anderson Cancer Center
HOUSTON — The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas…
-
Noosa News20 hours agoLuxury caravan manufacturer Zone RV collapses into administration
-
General21 hours agoWoman in her 20s dies after dog attack in Western Australia’s north
-
General7 hours agoBoard stacking allegations as RACP directors call snap meeting
-
General20 hours agoCase against teens charged over Adelaide shopping centre stabbing could move to adult court